- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05848284
Klinická bezpečnost a účinnost systému VDyne transkatétrové náhrady trikuspidální chlopně pro léčbu trikuspidální regurgitace (VISTA-US) (VISTA-US)
Klinická bezpečnost a účinnost systému náhrady trikuspidální chlopně VDyne Transkatétr pro léčbu trikuspidální regurgitace
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Vinny Podichetty
- Telefonní číslo: 763-777-5969
- E-mail: vpodichetty@vdyne.com
Studijní záloha kontaktů
- Jméno: Jeya Satheesh
- Telefonní číslo: 952-686-8158
- E-mail: jsatheesh@vdyne.com
Studijní místa
-
-
Quebec
-
Québec, Quebec, Kanada, G1V 4G5
- Nábor
- Québec-Université Laval (IUCPQ-ULaval)
-
Kontakt:
- Dominique Lachance Clinical Study Coordinator
- Telefonní číslo: 3055 (418) 656-8711
- E-mail: Dominique.Lachance@criucpq.ulaval.ca
-
Vrchní vyšetřovatel:
- Joseph Rodés, MD
-
-
-
-
California
-
Los Angeles, California, Spojené státy, 90048
- Nábor
- Cedars-Sinai Medical Center
-
Vrchní vyšetřovatel:
- Raj Makkar
-
Kontakt:
- Mitch Gheorghiu
- Telefonní číslo: 3104236152
- E-mail: Mitch.Gheorghiu@cshs.org
-
-
Michigan
-
Detriot, Michigan, Spojené státy, 48208
- Aktivní, ne nábor
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55407
- Aktivní, ne nábor
- Minneapolis Heart Institute Foundation
-
Rochester, Minnesota, Spojené státy, 55905
- Nábor
- Mayo Clinic - Rochester
-
Kontakt:
- Adam Logeman
- Telefonní číslo: 507-422-2263
- E-mail: Logeman.Adam@mayo.edu
-
-
New York
-
New York, New York, Spojené státy, 10032
- Nábor
- Columbia University Medical Center/NYPH
-
Vrchní vyšetřovatel:
- Torsten Vahl, MD
-
Kontakt:
- Treena Williams
- Telefonní číslo: 2123423485
- E-mail: taw2112@cumc.columbia.edu
-
The Bronx, New York, Spojené státy, 10467
- Nábor
- Montefiore Medical Center
-
Kontakt:
- Kara Booth
- Telefonní číslo: (718) 920-6523
- E-mail: kbooth@montefiore.org
-
Vrchní vyšetřovatel:
- Edwin Ho, MD
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- Nábor
- The Christ Hospital
-
Kontakt:
- Belinda Frakes
- Telefonní číslo: 5135851777
- E-mail: Belinda.frakes@thechristhospital.com
-
Vrchní vyšetřovatel:
- Santiago Garcia
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Nábor
- Oregon Health and Science Unversity
-
Vrchní vyšetřovatel:
- Firas Zahr, MD
-
Kontakt:
- Anna Garwood
- Telefonní číslo: 503-494-3472
- E-mail: garwood@ohsu.edu
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Nábor
- Medical University of South Carolina
-
Kontakt:
- Natalie Drain, MHA
- Telefonní číslo: 843-876-5037
- E-mail: drain@musc.edu
-
Vrchní vyšetřovatel:
- Nick Amoroso, MD
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37205
- Nábor
- Ascension St. Thomas
-
Vrchní vyšetřovatel:
- Andrew Morse, MD
-
Kontakt:
- Erin Beller, BSN, RN
- Telefonní číslo: 6152226997
- E-mail: erin.beller@ascension.org
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Symptomatic severe tricuspid valve regurgitation of primary or secondary etiology.
- NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
- Subject is adequately treated with medical therapy for heart failure ≥ 30 days prior to
- index procedure, including a diuretic.
- Heart Team determines patient is a recommended candidate for the VDyne System.
- Age >18 years at time of index procedure.
- Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.
Exclusion Criteria:
- Patient anatomy (cardiac and vascular) is not suitable for VDyne System as assessed by Imaging Core Labs, Sponsor or Clinical Screening Committee (CSC)
- Intolerance to procedural anticoagulation or post-procedural antiplatelet/ anticoagulation regimen that cannot be medically managed
- Hypersensitivity to nickel or titanium
- Left Ventricular Ejection Fraction (LVEF) <30%.
- Severe RV dysfunction.
- Significant abnormalities of the tricuspid valve and sub-valvular apparatus.
- Sepsis including active infective endocarditis (IE) (within last 6 months).
- Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
- Severe tricuspid annular or leaflets calcification.
- Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg.
- History or rheumatic fever
- Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease.
- Any planned surgery or interventional procedure within 30 days prior to or 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as CABG, PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.
- Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound).
- Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
- Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
- Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
- Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.).
- Significant valvular heart disease requiring intervention other than the tricuspid valve.
- Known significant intracardiac shunt (e.g. septal defect)
- Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure.
- Severe lung disease (severe COPD or continuous use of home oxygen or oral steroids).
- Acute myocardial infarction (AMI) within 30 days.
- Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis.
- End-stage liver disease (MELD > 11 / CHILD class C).
- Bleeding requiring transfusion within prior 30 days.
- Coagulopathy or other clotting disorder that cannot be medically managed.
- Chronic immunosuppression or other condition that could impair healing response.
- Any of the following: leukopenia, chronic anemia (Hgb < 9), thrombocytopenia, history of bleeding diathesis, or coagulopathy.
- Unwilling to receive blood products.
- Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically.
- Life expectancy less than 12 months due to non-cardiac comorbidities.
- Treatment is not expected to provide benefit (futile).
- Current IV Drug user (must be free drug abuse for > 1 year).
- Pregnant, lactating or planning pregnancy within next 12 months.
- Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees).
- Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study.
- Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment.
- Patient unable or unwilling to comply with study required testing and follow-up visits
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: VDyne System Treatment Arm
Device |
The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
Časové okno: Implant to 30 days post-procedure
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC). |
Implant to 30 days post-procedure
|
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Časové okno: Baseline to 1 month after implant
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs |
Baseline to 1 month after implant
|
|
Changes in symptom status (NYHA class)
Časové okno: Baseline to 1 month after implant
|
Changes in symptom status (NYHA class) |
Baseline to 1 month after implant
|
|
Changes in functional capacity (6-minute walk test)
Časové okno: Baseline to 1 month after implant
|
Changes in functional capacity (6-minute walk test) |
Baseline to 1 month after implant
|
|
Changes in in quality of life (KCCQ score)
Časové okno: Baseline to 1 month after implant
|
Changes in in quality of life (KCCQ score). A higher score indicates worsening quality of life outcomes |
Baseline to 1 month after implant
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC).
Časové okno: 30 days post-procedure to 1 year
|
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC). |
30 days post-procedure to 1 year
|
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Časové okno: 1 month after implant to 1 year post-implant
|
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs |
1 month after implant to 1 year post-implant
|
|
Changes in right ventricle as measured by core lab
Časové okno: 1 month after implant to 1 year post-implant
|
Changes in the right ventricle as measured by core lab |
1 month after implant to 1 year post-implant
|
|
Rate of heart failure hospitalization
Časové okno: 1 month after implant to 1 year post-implant
|
Rate of heart failure hospitalization |
1 month after implant to 1 year post-implant
|
|
Changes in symptom status (NYHA class)
Časové okno: 1 month after implant to 1 year post-implant
|
Changes in symptom status (NYHA class) |
1 month after implant to 1 year post-implant
|
|
Changes in functional capacity (6-minute walk test)
Časové okno: 1 month after implant to 1 year post-implant
|
Changes in functional capacity (6-minute walk test) |
1 month after implant to 1 year post-implant
|
|
Changes in in quality of life (KCCQ score).
Časové okno: 1 month after implant to 1 year post-implant
|
Changes in in quality of life (KCCQ score). A higher score indicates worsening outcomes |
1 month after implant to 1 year post-implant
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- TPR0037-P
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .